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Dear Sir,
Hepatitis B virus infection has remained
a serious threat to maintenance hemodialy-
sis patients in spite of improvements in in-
fection control and dialysis techniques. Mul-
tiple reasons may explain the persistence of
this problem. Hemodialysis patients are at a
greater risk of infection, the seroconversion
rate after vaccination is still less than in the
general population (50–75 versus 95%) and
the duration of immunity is shorter [1].
The lack of response to hepatitis B vac-
cine may arise from reduced costimulation
and effector activation of T cells and corre-
lates with an increased production of proin-
flammatory cytokines by monocytes [2, 3].
There is considerable evidence that endotox-
in fragments and other bacterial products
derived from contaminated dialysis fluid
can cross dialyzer membranes and induce
enhanced cytokine release by monocyte acti-
vation [4]. This cytokine release may be cir-
cumvented by the use of on-line produced
ultrapure dialysis fluid, which results in a
lower systemic inflammatory response [5,
6].
The purpose of our prospective random-
ized investigation was to test the hypothesis
that the microbiological quality of dialysis
fluid affects the response to hepatitis B vac-
cination.
Patients with end-stage renal disease re-
ceiving hemodialysis were eligible. Inclu-
sion criteria were as follows: hepatitis B sur-
face antigen (HbsAg) negative, antibody to
HbsAg negative and no previous hepatitis
vaccination. Exclusion criteria were acute or
chronic inflammatory disorders or infec-
tions, use of immunosuppressive drugs and
malignancy. 72 early hemodialysis patients
(32 female, 40 male; age 62 B 8 years) gave
informed consent. Patients were randomly
assigned to either conventional, i.e. poten-
tially contaminated, dialysis fluid or ultra-
pure dialysis fluid (produced on-line by one-
step additional ultrafiltration using an endo-
toxin-adsorbing polysulfone filter). All pa-
tients received hemodialysis 3 times per
week (Kt/V of at least 1.2) utilizing volu-
metrically controlled ultrafiltration (MTS
4008, Fresenius, Oberursel, Germany) and
high-flux polysulfone dialyzers (APS 650
Asahi, Tokyo, Japan). The vaccination
schedule encompassed four doses of 40 Ìg of
recombinant hepatitis B vaccine (Gen H-B-
Vax D, Aventis Pasteur MSD, Leimen, Ger-
many) given at 0, 1, 2 and 6 months in the
deltoid muscle. Antibody titers to HbsAg
were measured by the AUSAB IMX system
(Abbott Laboratories, Chicago, Ill., USA)
one month after the last dose. An antibody
titer of 10 IU/l or more represented serocon-
version. The nonconverters were those who
did not reach an antibody titer of 10 IU/l or
more after completion of the vaccination
program. Laboratory tests [hemoglobin, in-
tact parathyroid hormone (PTH), serum al-
bumin], calculation of body mass index and
EPO doses were determined as previously
described [7]. Statistical significance was cal-
culated for differences between means using
an unpaired t test and for observed/expected
frequencies by means of ¯2 analysis (two-
tailed Fisher’s exact test). A p value of less
than 0.05 was considered significant. All val-
ues in tables are expressed as means B SD.
There were no statistically significant dif-
ferences in age, gender, body weight, etiology
of renal disease, time on hemodialysis, Kt/V,
hemoglobin concentration, number of pa-
tients receiving EPO, intact PTH levels or
parameters of nutritional status between the
two study groups. The ultrapure dialysis
fluid group, however, had significantly lower
CRP and IL-6 concentrations and need for
rHuEPO (table 1).
The overall seroconversion rate was 78%
(56 out of 72 patients). Of these 56, 32
patients were in the ultrapure dialysis fluid
group and 24 patients were in the conven-
tional mildly contaminated dialysis fluid
group (89 vs. 67%; Fisher’s exact two-tailed
test, p = 0.045). The antibody titers obtained
4 weeks after the last vaccination dose were
significantly higher in the ultrapure dialysis
fluid group (table 2). In 8 out of the 12 non-
responding patients of the conventional
dialysis fluid group, seroconversion was
achieved by a second vaccination protocol
(identical to the first) after switching to ultra-
pure dialysis fluid.
Our prospective randomized investiga-
tion demonstrates that the use of ultrapure
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dialysis fluid results in a higher seroconver-
sion rate in response to intramuscular vacci-
nation against hepatitis B virus in early
maintenance hemodialysis patients. The dif-
ferences in the rate of seroconversion be-
tween the two groups could not be explained
by differences in the demographic or renal
characteristics of the two study groups.
Moreover, there was no evidence of under-
dialysis, malnutrition, excessive hyperpara-
thyroid hormone secretion or lower inci-
dence of rHuEPO therapy. Our data indicate
that endotoxins derived from mildly con-
taminated dialysis fluid are related to in-
creased cytokine release by monocyte activa-
tion and contribute to the uremia-associated
immune defect.
In the past, a number of measures have
been taken to increase the seroconversion
rate and duration of immunity against hepa-
titis B virus vaccination in end-stage renal
disease patients [1]. They consisted of an
increased number of doses, increased anti-
gen load per dose, different routes of admin-
istration (intradermally vs. intramuscularly),
addition of IL-2 to the protocol or vaccina-
tion earlier in the course of progressive renal
failure. However, these different approaches
have not been successful in a reproducible
way. However, any decrease in the incidence
of hepatitis B virus infection depends exclu-
sively on immunity to hepatitis B virus in-
fection by successful vaccination [8]. Ultra-
pure dialysis offers a safe and cost-efficient
strategy to increase the immunity to hepati-
tis B in end-stage renal disease.
In conclusion, the present investigation
demonstrated for the first time that a high
conversion rate and high titer response to
hepatitis B vaccination can be achieved in
end-stage renal disease patients treated with
ultrapure dialysis fluid.
Table 1. Patient characteristics at recruitment
Ultrapure dialysis
fluid group
Conventional dialysis
fluid group
36 36
Age, years 64B10 60B6
Gender (female/male) 15/21 17/19
BMI, kg/m2 24B3 26B5
Etiology of renal disease (major type)
Chronic glomerulonephritis 10 8
Nephroangiosclerosis 8 7
Diabetes mellitus 7 8
Polycystic kidney disease 4 3
Tubulo-interstitial nephritis 4 4
Time on hemodialysis, months 6B2 5B3
Kt/V 1.3B0.1 1.2B0.1
Hemoglobin, g/dl 10.4B0.6 10.2B0.8
Number of patients on rHuEPO 26 25
Dose of rHuEPO, U/kg/week 62B4* 98B18
Intact PTH, pg/ml 104B45 96B38
Serum albumin, g/dl 4.0B0.3 3.8B0.2
CRP, mg/dl 0.6B0.2* 1.2B0.4
IL-6, pg/ml 14B4* 45B6
BMI = Body mass index.
* p ! 0.05 versus corresponding values in patients receiving conventional dialysis fluid.
Table 2. Antibody titers after vaccination in responding patients
receiving different dialysis fluids
Ultrapure dialysis
fluid group
Conventional dialysis
fluid group
32* 24
Antibody titer, IU/l 616B123* 268B108
* p ! 0.05 versus corresponding values in patients receiving con-
ventional dialysis fluid.
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